XML 33 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]
Principles of Consolidation
 
The accompanying consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics, B.V., which was organized in the Netherlands in
March 2015.
Heron Therapeutics, B.V. has
no
operations and
no
material assets or liabilities, and there have been
no
significant transactions related to Heron Therapeutics, B.V. since its inception.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, inventory and related reserves, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.
Cash, Cash Equivalents, and Short-Term Investments [Policy Text Block]
Cash,
Cash Equivalents
and Short-Term Investments
 
Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of
three
months or less from the original purchase date.
 
Short-term investments consist of securities with contractual maturities of greater than
three
months to
one
year from the original purchase date. We have classified our short-term investments as available-for-sale securities in the accompanying consolidated financial statements. Available-for-sale securities are stated at fair market value, with the net change in unrealized gains and losses reported in other comprehensive loss and realized gains and losses included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
 
Our bank and investment accounts have been placed under control agreements in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) (see Note
8
).
Fair Value Measurement, Policy [Policy Text Block]
Fair Value of Financial Instruments
 
A company
may
elect to use fair value to measure accounts and loans receivable, available-for-sale and held-to-maturity securities, equity method investments, accounts payable, guarantees and issued debt. Other eligible items include firm commitments for financial instruments that otherwise would
not
be recognized at inception and non-cash warranty obligations where a warrantor is permitted to pay a
third
party to provide the warranty goods or services. If the use of fair value is elected, any upfront costs and fees related to the item such as debt issuance costs must be recognized in earnings and cannot be deferred. The fair value election is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects
not
to measure based on fair value. Unrealized gains and losses on existing items for which fair value has been elected are reported as a cumulative adjustment to beginning retained earnings and any changes in fair value are recognized in earnings. We have elected to
not
apply the fair value option to our financial assets and liabilities.
 
Financial instruments, including cash and cash equivalents, receivables, inventory, prepaid expenses, other current assets, accounts payable and accrued expenses, are carried at cost, which is considered to be representative of their respective fair values because of the short-term maturity of these instruments. Short-term available-for-sale investments are carried at fair value (see Note 
3
). Our Convertible Notes outstanding at
December 
31,
 
2018
do
not
have a readily available ascertainable market value, however, the carrying value is considered to approximate its fair value.
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
 
Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits
may
be in excess of insured limits. We
may
also invest our excess cash in money market funds, U.S. government and agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
 
Our products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell our products to healthcare providers and hospitals, the end users.
 
The following table includes the percentage of net product sales and accounts receivable balances for our
three
major Customers, each of which comprised
10%
or more of our net product sales:
 
   
Net Product Sales
    
Accounts Receivable
  
   
Year Ended December 31
, 2018
    
As of December 31
, 2018
  
                 
Customer A
    
41.7
 %    
38.7
 %
Customer B
    
34.9
 %    
46.1
 %
Customer C
    
22.5
 %    
14.8
 %
Total
    
99.1
 %    
99.6
 %
Receivables, Policy [Policy Text Block]
Accounts Receivable, Net
 
Accounts receivable are recorded at the invoice amount, net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for doubtful accounts, we consider: (
1
) our historical experience with collections and write-offs; (
2
) the credit quality of our Customers and any recent or anticipated changes thereto; and (
3
) the outstanding balances and past due amounts from our Customers.
 
We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in
October 2016
and
January 2018,
respectively, in anticipation of the timing in reimbursement by government and commercial payers. Effective
January 2018,
we shortened payment terms to certain of our SUSTOL Customers. As of
December 31, 2018,
extended payment terms given to our Customers were evaluated in accordance with GAAP and did
not
impact the collectability of accounts receivables.
 
As of
December 31, 2018,
we determined that an allowance for doubtful accounts was
not
required. For the year ended
December 31, 2018,
we did
not
write off any accounts receivable balances.
Inventory, Policy [Policy Text Block]
Inventory
 
Inventory is stated at the lower of cost or estimated net realizable value on a
first
-in,
first
-out, or FIFO, basis. We periodically analyze our inventory levels and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory quantities that are in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory
may
be required, which would be recorded as cost of product sales.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
 
Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (generally
five
years). Leasehold improvements are stated at cost and amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
 
If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and record the impairment as a reduction in the carrying value of the related asset with a corresponding charge to operating expenses. Estimating the undiscounted future operating cash flows associated with long-lived assets requires judgment and assumptions that could differ materially from actual results.
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
 
In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.
2014
-
09,
Revenue from Contracts with Customers
(“Topic
606”
). Topic
606
is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic
606
is effective for fiscal years beginning after
December 15, 2017,
including interim periods within those fiscal years. Accordingly, in the
first
quarter of
2018,
we adopted Topic
606
using the modified retrospective approach. Under this approach, incremental disclosures are provided to present each financial statement line item for
2018
under the prior standard. As a result of the adoption of Topic
606,
we recorded a cumulative adjustment to accumulated deficit of
$1.6
million on
January 1, 2018.
This adjustment reflects the acceleration of
$2.9
 million in gross product sales less
$1.1
 million in product sales allowances and
$0.2
million in cost of product sales (see Note
5
).
Clinical Trial Accruals [Policy Text Block]
Accrued Clinical Liabilities
 
We accrue clinical costs based on work performed, which relies on estimates of the progress of the trials and the related expenses incurred. Clinical trial related contracts vary significantly in duration, and
may
be for a fixed amount, based on the achievement of certain contingent events or deliverables, a variable amount based on actual costs incurred, capped at a certain limit or contain a combination of these elements. Revisions are recorded to research and development expense in the period in which the facts that give rise to the revision become known. Historically, revisions have
not
resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a clinical trial could result in a material charge to our results of operations.
Research and Development Expense, Policy [Policy Text Block]
Research and Development Expense
 
All costs of research and development are expensed in the period incurred. Research and development expense primarily consist of personnel and related costs, stock-based compensation expense, fees paid to outside service providers and consultants, facilities costs and materials used in clinical and preclinical trials and research and development.
Legal Costs, Policy [Policy Text Block]
Patent Costs
 
 
We incur outside legal fees in connection with filing and maintaining our various patent applications. All patent costs are expensed as incurred and are included in general and administrative expense in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation Expense
 
We estimate the fair value of stock-based payment awards using the Black-Scholes option pricing model. This fair value is then amortized using the straight-line single-option method of attributing the value of stock-based compensation to expense over the requisite service periods of the awards. The Black-Scholes option pricing model requires the input of complex and subjective assumptions, including each option’s expected life and price volatility of the underlying stock.
 
 
As stock-based compensation expense is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on historical data.
Warrants Issued in Equity Financings [Policy Text Block]
Warrants
 
We have issued warrants to purchase shares of our common stock in conjunction with certain equity financings or in exchange for services. The terms of the warrants were evaluated to determine the appropriate classification as equity or a liability.
Income Tax, Policy [Policy Text Block]
Income Taxes
 
We recognize the impact of a tax position in our consolidated financial statements if the position is more likely than
not
to be sustained on examination and on the technical merits of the position. The total amount of unrecognized tax benefits, if recognized, would affect other tax accounts, primarily deferred taxes in future periods, and would
not
affect our effective tax rate, since we maintain a full valuation allowance against our deferred tax assets (see Note
10
). We recognize interest and penalties related to income tax matters in income tax expense.
Comprehensive Income, Policy [Policy Text Block]
Comprehensive
Loss
 
Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive net loss for all periods presented.
Earnings Per Share, Policy [Policy Text Block]
Net Loss
per Share
 
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and shares of common stock underlying Convertible Notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.
 
Because we have incurred a net loss for all periods presented in the consolidated statements of operations and comprehensive loss, the following common stock equivalents were
not
included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):
 
   
December 31
,
  
   
2018
    
2017
    
2016
  
                         
Stock options outstanding
    
15,265
      
13,463
      
11,845
  
Warrants outstanding
    
640
      
620
      
600
  
Shares of common stock underlying Convertible Notes outstanding
    
8,473
      
7,983
      
7,521
  
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
 
Recently Adopted
 
In
May 2017,
the FASB issued ASU
No.
2017
-
09,
Compensation – Stock Compensation: Scope of Modification Accounting
(“ASU
2017
-
09”
).
The amendments in ASU
2017
-
09
provide guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic
718.
In the
first
quarter of
2018,
we adopted the provisions of ASU
2017
-
09,
which did
not
have a material impact on our results of operations or financial condition.
 
Not
Yet Adopted
 
In
February 2016,
the FASB issued ASU
No.
2016
-
02,
Leases (Topic
842
)
(“ASU
2016
-
02”
),
which provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In
July 2018,
the FASB issued ASU
No.
2018
-
11,
Leases (Topic
842
): Targeted Improvements
and ASU
No.
2018
-
10,
Codification Improvements to Topic
842,
Leases
. ASU
2016
-
02
and the subsequent modifications are identified as “ASC
842.”
ASC
842
requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or
not
the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than
twelve
months, regardless of classification. Leases with a term of
twelve
months or less will be accounted for similar to existing guidance for operating leases. ASC
842
is effective for fiscal years beginning after
December 15, 2018,
including interim periods within those fiscal years. We adopted the provisions of ASU
2016
-
02
on
January 1, 2019
using the alternative modified transition method. We are still in the process of finalizing our assessment of the impact of ASC
842
on our results of operations and related disclosures. We are also implementing additional internal controls to enable future preparation of financial information and disclosures in accordance with ASC
842.
 
In
August 2018,
the FASB issued ASU
No.
2018
-
13,
Fair Value Measurement (Topic
820
) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement
(“ASU
2018
-
13”
), which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU
2018
-
13
is effective for fiscal years beginning after
December 15, 2019,
including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the provisions of ASU
2018
-
13
in the
first
quarter of
2020,
and we are currently evaluating the impact on our consolidated financial statements.